Monograph Details
|
|
Musculoskeletal Disorders
> Arthritis/rheumatic disorders
|
|
NAPROSYN SUSPENSION |
| Manufacturer |
|
Roche Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
NSAID (arylacetic acid deriv.). |
| Generic Name |
|
Naproxen 125mg/5mL; pineapple-orange flavor. |
| Also |
• EC-NAPROSYN
• NAPROSYN
|
| Indications |
|
Rheumatoid arthritis. Osteoarthritis. Ankylosing spondylitis. Juvenile rheumatoid arthritis (JRA). Tendinitis. Bursitis. Acute gout. |
| Children |
|
<2yrs: not recommended. ≥2yrs: JRA: 5mg/kg twice daily. Other uses: Doses of 2.5–5mg/kg/dose, max 15mg/kg/day have been used. |
| Adults |
|
Arthritis, spondylitis: 250–500mg twice daily; max 1.5g/day (up to 6 months). Tendinitis, bursitis: 500mg once, then 500mg twice daily or 250mg every 6–8 hrs; max (first day) 1.25g, then max 1g/day. Acute gout: 750mg once, then 250mg every 8 hrs. |
| Contraindications |
|
Aspirin allergy. Coronary artery bypass graft surgery. |
| Precautions |
|
Advanced renal disease: not recommended. Active peptic ulcer. History of GI or inflammatory bowel disease. Impaired renal or hepatic function. Heart failure. Edema. Hypertension. Preexisting asthma. Bleeding disorders. Monitor blood, hepatic, renal, and ocular function in chronic use. Elderly. Debilitated. Pregnancy (Cat.C); avoid in late pregnancy. Nursing mothers: not recommended. |
| Interactions |
|
Avoid concomitant aspirin. May potentiate protein-bound drugs (eg, hydantoins, sulfonamides, sulfonylureas). Monitor oral anticoagulants. Increased risk of GI bleeding with oral corticosteroids, SSRIs, smoking, alcohol. May antagonize diuretics, β-blockers, other antihypertensives. Increased renal toxicity with ACE inhibitors. Methotrexate excretion reduced. Increases serum lithium levels. Probenecid increases plasma levels and delays elimination. Concomitant H2 blockers, sucralfate, intensive antacid therapy: use immediate-release forms of naproxen. Cholestyramine may delay absorption. |
| Adverse Reactions |
|
GI bleeding, peptic ulcer, constipation, heartburn, abdominal pain, nausea, headache, dizziness, drowsiness, pruritus, rash (discontinue if occurs), tinnitus, edema, nephritis, nephrotic syndrome, jaundice, hepatitis. See literature re: risk of cardiovascular events. |
| How Supplied |
Tabs—100
Susp—pt
EC—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
